Biotechnology is a modern interdisciplinary high-tech based on life sciences, applying biological principles and modern engineering techniques, using biological systems to process a variety of products for human use.

In recent years, life science research and biotechnology development have made major breakthroughs, opening a new path as a powerful tool to solve problems casued by social development in areas of health, food, energy, ecology and environment. Nowadays, the momentum of biotechnology is in high demand. The New Horizon Holdings Group is currently focusing on two directions: plant essence extractions (Australian native plant and Medicinal Cannabis) and manufacturing of complementary medicines.

New Horizon Biotechnology Pty Ltd

Founded in 2018, New Horizon Biotechnology Pty Ltd is the first commercial-scale extraction company in Australia, mainly engaged in processing and manufacturing of medicinal cannabidiol (CBD), raw materials for complementary medicines and manufacturing of healthcare products.

The company is headquartered in Melbourne, the capital city of Victoria on 101 Rathdowne Street, Carlton. Its extraction factory is located in the suburb of Elizabeth South, 25 kilometers away from Adelaide, South Australia, which covers an area of approximately 10,000 square meters and meets the highest international TGA standards.

New Horizon Biotechnology has received strong support from the South Australian Government and the Australian Federal Government. The applied medicinal cannabis cultivation, manufacturing and import and export licenses have entered fast-track processing channel and are expected to be obtained by early 2020.

Team members of New Horizon Biotechnology are elites from various industries, including plant science professors, horticulturalist, plant extraction experts, pharmaceutical and medical professionals, researchers, lawyers, and highly skilled technicians. The company will develop the full potential in medicinal cannabis cultivation, processing and import and export industries while researching and expanding innovative Australian native plant extracts as raw materials for complementary medicines.

As an emerging industry, the geographic and agricultural advantages of Australia and New Zealand have placed these two countries at a superior position for capital investment and rapid growth. Australia's medicinal cannabis and industrial hemp market is expected to increase from $52 million in 2018 to $1.2 billion in 2027, ranking fifth in the world. New Horizon Biotechnology is committed to become Australia’s leading biomedical and healthcare technology company, large-scale processing manufacturer and importer and exporter of pharmaceutical CBD, providing its customers with low-cost, high-purity CBD and plant extracts.